Invigorating Lives
About Menarini Group

About Menarini Group

Menarini is the largest Italian multinational biopharmaceutical company with nearly 16,000 employees worldwide and presence in more than 100 countries, including Europe, Africa, Middle East, Asia-Pacific, Central and Latin America.

Founded in 1886, Menarini markets products in key therapeutic fields including respiratory, cardiovascular, gastroenterology, metabolism, antibiotics, diabetes, anti-inflammatories and analgesics.

Featured Launch

Featured Launch

Menarini launched into Men’s Health with the first and only drug specifically developed to treat Premature Ejaculation (“PE”), now approved in over 60 countries.  In Asia-Pacific, the drug has been launched in Australia, China, Hong Kong, Korea, Malaysia, Singapore, and Taiwan.  PE affects nearly 1 in 3 men in Asia-Pacific but is often under detected and under treated.  Based on robust clinical trials involving over 16,000 men worldwide, Menarini’s Rx treatment for PE is proven to be well-tolerated and to significantly improve control over ejaculation and sexual satisfaction for the couple.

Invida Rebrands to Menarini

Invida Rebrands to Menarini

Invida Holdings announced its name change to A. Menarini Asia-Pacific Holdings Pte. Ltd. on 6 December 2012. The brand transformation reflects its alignment with parent, Menarini Group, and allows for the promotion of a single, unified brand in the global marketplace. “We are proud to build on Menarini’s more than 125 years of history, bringing Menarini”s products and expertise into our already established operations in Asia-Pacific,”said John A. Graham, CEO of Menarini Asia-Pacific.

Welcome

Menarini is the world’s largest Italian biopharmaceutical company, focused on delivering differentiated ethical and consumer healthcare brands across the region. With over 3,000 professionals in 13 major markets, Menarini Asia-Pacific operates across the entire commercial value chain, from regulatory approval and product launch to lifecycle management and offers an unparalleled customer experience to partners wanting to tap into the Asia-Pacific growth story.

READ MORE
Corporate Video

Latest Updates
Three Visiting Experts Urge Women to Get Their Partners Treated for Premature Ejaculation

Singapore, 7 March 2014 – The facts and figures are in: Singaporean women just aren’t sexually satisfied. According to published studies on premature ejaculation (PE), it affects 34% of men in Singapore at some point in their lives.

READ MORE
Moberg Pharma and Menarini Extend Distribution Agreement for Kersal Nail to South East Asia

Singapore, 14 February 2014 – Moberg Pharma AB (OMX: MOB) and Menarini Asia-Pacific, a member of the Menarini Group are pleased to announce that Menarini Asia-Pacific has been granted the exclusive rights to market and sell Kerasal Nail™ in eight Southeast Asian countries.

READ MORE
Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia as First Clinical Development Candidate in $1 Billion Oncology Investment Alliance

Oxford BioTherapeutics (OBT) and Berlin-Chemie (Menarini Group) announce today that they have designated a novel enhanced antibody targeting acute myeloid leukemia (AML) as the first clinical development candidate under the companies’ strategic oncology collaboration.

READ MORE

Follow:   Youtube Youtube